deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT00317512

Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

A Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Dose Finding Pilot Study, to Evaluate Safety/Feasibility of HBOC-201 in Elective Percutaneous Coronary Revascularization of Subjects With Acute Coronary Syndromes

Sponsor: Biopure Corporation

Conditions Angina Pectoris Myocardial Infarction Unstable Angina
Interventions Hemoglobin-Based Oxygen Carrier-201 (HBOC-201) Percutaneous Coronary Revascularization Voluven
Updated 6 times since 2017 Last updated: May 15, 2008 Started: Dec 31, 2003 Primary completion: Apr 30, 2005 Completion: Jul 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Angina Pectoris and Myocardial Infarction, this trial is completed. The trial is conducted by Biopure Corporation and has accumulated 6 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biopure Corporation
Data source: Biopure Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations